Elena Barengolts
Endocrinology, Diabetes & Metabolism · Chicago, ILNPI 1942305313
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.4% of the total across 212 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,958, 6.9 times the $427 reported in 2019.
Across 212 payments — averaging $35.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$984
- Amgen$456
- AstraZeneca$416
- Sanofi-aventis U.S. LLC$394
- Abbott$364
- plus $4K from 35 others
Across 19 payments — averaging $9657.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$162K
- Lexicon Pharmaceuticals, Inc.$19K
- AbbVie$3K
What the payments were for
- Speaking & faculty fees$3755%
- Travel & lodging$210%
- Food & beverage$7,03194%
- Education$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 33 | $1,317 |
| Lilly USA, LLC | 21 | $984 |
| Amgen(2 entities) | 37 | $456 |
| AstraZeneca(2 entities) | 11 | $416 |
| Sanofi-aventis U.S. LLC | 2 | $394 |
| Abbott | 9 | $364 |
| Bayer | 8 | $286 |
| Boehringer Ingelheim | 3 | $281 |
| Insulet Corporation | 6 | $235 |
| Ascendis Pharma Endocrinology Inc | 5 | $207 |
| Lexicon Pharmaceuticals, Inc. | 4 | $201 |
| Kyowa Kirin, Inc. | 3 | $164 |
| Medtronic | 1 | $152 |
| Recordati_rare_diseases_inc. | 3 | $147 |
| UCB, Inc. | 8 | $147 |
| Xeris Pharmaceuticals, Inc. | 2 | $141 |
| GSK | 2 | $138 |
| Regeneron Healthcare Solutions, Inc. | 6 | $134 |
| Dexcom, Inc. | 3 | $134 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $125 |
| Kowa Pharmaceuticals America, Inc. | 1 | $122 |
| Madrigal Pharmaceuticals | 4 | $112 |
| Mannkind Corporation | 5 | $97 |
| Sanofi | 4 | $82 |
| Tandem Diabetes Care, Inc. | 4 | $80 |
| Radius Health, Inc. | 4 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $68 |
| Corcept Therapeutics | 2 | $63 |
| Merck | 3 | $53 |
| Phadia US Inc. | 2 | $33 |
| Boston Scientific | 1 | $32 |
| Cequr Corporation | 2 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| Kaleo, Inc. | 1 | $25 |
| Alvogen Inc | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Alk-abello, Inc | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Cranial Technologies, Inc | 1 | $15 |
| Sobi, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$489
- MOUNJARO$481
- NO PRODUCT DISCUSSED$375
- FREESTYLE LIBRE 3$275
- Wegovy$247
- Ozempic$224
- MINIMED 780G$152
- Omnipod$145
- Kerendia$131
- RYBELSUS$125
- Inpefa$125
- Yorvipath$125
- NUCALA$125
- NEFFY$125
- FARXIGA$124
- ZORYVE$122
- GVOKE HYPOPEN$122
How this compares
$7,446 in reported general payments places this provider in the 80th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 260 | $319,437 |
| JardianceEmpagliflozin | 254 | $232,444 |
| FarxigaDapagliflozin Propanediol | 167 | $163,312 |
| RybelsusSemaglutide | 105 | $125,396 |
| JanuviaSitagliptin Phosphate | 100 | $78,468 |
| MounjaroTirzepatide | 30 | $38,894 |
| TradjentaLinagliptin | 31 | $27,403 |
| JanumetSitagliptin Phos/Metformin Hcl | 27 | $19,463 |
| TrulicityDulaglutide | 13 | $12,274 |
| KerendiaFinerenone | 12 | $10,519 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $6,045 |
| Glimepiride | 415 | $5,678 |
| DapagliflozinDapagliflozin Propanediol | 11 | $5,630 |
| Humalog Kwikpen U-100Insulin Lispro | 27 | $5,036 |
| Pioglitazone Hcl | 314 | $4,489 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,317 | $444,833365 claims |
| Boehringer IngelheimJardiance, Tradjenta | $281 | $259,847285 claims |
| AstraZenecaFarxiga | $416 | $163,312167 claims |
| MerckJanuvia, Janumet | $53 | $97,931127 claims |
| Lilly USA, LLCMounjaro, Trulicity | $984 | $51,16743 claims |
| BayerKerendia | $286 | $10,51912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
Other endocrinology, diabetes & metabolism in Chicago
- Wahid KassarChicago$884K
- George BakrisChicago$403K
- Wenyu HuangChicago$341K
- Silvana PannainChicago$226K
- Grazia AleppoChicago$162K
- Tamara VokesChicago$139K
- Emily SmithChicago$112K
- Antonio BiancoChicago$111K
- Aaron BenjaminChicago$105K
- David OyerChicago$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.